Scott Honken, Calibrate president and chief commercial officer

Amid GLP-1 ma­nia, health tech's weight loss star­tups are try­ing to prove their ser­vices mat­ter

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) 

The ram­pant suc­cess of new pre­scrip­tion GLP-1 drugs has turned out to be both a tail­wind and a huge risk for health tech’s emerg­ing group of weight loss man­age­ment com­pa­nies.

Cal­i­brate, which made its name as a place where peo­ple could go to get ac­cess to the drugs in the ear­ly days of ap­provals, is in­creas­ing­ly fac­ing com­pe­ti­tion from com­pa­nies like Noom and Weight­Watch­ers — and even drug­mak­er Eli Lil­ly to be the place to go when seek­ing pre­scrip­tion weight loss care. To stay com­pet­i­tive, Cal­i­brate and com­pa­nies like it have to show ev­i­dence that their ap­proach­es go fur­ther than pro­vid­ing ac­cess to weight loss med­ica­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.